On Monday, Following Stocks were among the “Top 100 Losers” In U.S. Stock Exchange: TESARO (NASDAQ:TSRO), Biogen Idec (NASDAQ:BIIB), Merrimack Pharmaceuticals (NASDAQ:MACK), Pilgrim’s Pride (NASDAQ:PPC)
Formerly On March 9, 2015 TESARO Inc (NASDAQ:TSRO) uncovered the closing of its previously disclosed underwritten public offering of ordinary stock. TESARO sold 3,755,000 shares of ordinary stock at an offering price to the public of $51.00 per share, which comprised of 355,000 shares of ordinary stock sold following the partial exercise of the underwriters’ over-allotment option to purchase up to 510,000 additional shares. TESARO estimates that the net proceeds from the offering will be about $179.7 million, after deducting the underwriting discount and other offering expenses payable by TESARO and subject to any future exercise of the remaining portion of the underwriters’ over-allotment option. Citigroup, Leerink Partners and Deutsche Bank Securities acted as joint book-running managers for the offering, with BMO Capital Markets, Robert W. Baird & Co. Incorporated and Mizuho Securities acting as co-managers for the offering.
TESARO Inc (NASDAQ:TSRO) decreased -2.59%, and closed at $58.67. The company holds the market capitalization of $2.40B. For the last twelve months, the stock was able to keep return on equity at -114.00%, while return on assets at -75.20%. Its 20-day moving average decreased gained 5.34%, below 50-day moving average of 26.49%, below 200-day moving average of 71.20% from the latest market price of $58.67. The mean recommendation of analysts for this stock is 1.30. (Where 1=Buy, 5=Sale).
TESARO Inc (TSRO) an oncology-focused biopharmaceutical corporation, identifies, attains, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States and internationally.
Biogen Idec Inc (NASDAQ:BIIB)’s shares picked down -2.57%, and closed at $463.73. The stock volatility for the week is 3.14%, while for the month remained 2.27%. The company holds consensus target price of $460.48.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed 12.38 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 58.40% and Annual EPS growth for the past 5 years is considered as 29.90%.
The mean recommendation of analysts for this stock is 2.00. (Where 1=Buy, 5=Sale).
Biogen Idec Inc (BIIB) discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. It provides AVONEX to treat relapsing multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn’s disease; PLEGRIDY to treat relapsing MS; TECFIDERA to treat MS; FAMPYRA to improve walking in adult patients with MS; ALPROLIX to treat hemophilia B; ELOCTATE to treat hemophilia A; RITUXAN for treating non-Hodgkin’s lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), in addition to two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with formerly untreated CLL; and FUMADERM to treat severe plaque psoriasis in adult patients.
Formerly On March 11, 2015 Pilgrim’s Pride Corporation (NASDAQ:PPC) uncovered it has closed an offering of $500.0 million aggregate main amount of Senior Unsecured Notes due 2025 (the “Notes”) to qualified institutional buyers in accordance with Rule 144A and Regulation S under the Securities Act of 1933, as amended (the “Securities Act”). The Notes will bear interest at a rate of 5.750% per year, payable semi-annually in arrears on March 15 and September 15 of each year, startning on September 15, 2015.
Pilgrim’s Pride Corporation (NASDAQ:PPC) declined -2.57%, and closed at $26.15. The company has the market capitalization of $6.97 billion. The beta value of the stock is 0.87. On the other hand the stock’s volatility for the week is 4.19%, and for the month is 3.73%. The stock’s price to book ratio is $3.09, however price to sale ratio is $0.79. Analyst’s mean recommendation regarding this stock is 2.60. (Where 1=Buy, 5=Sale).
Pilgrim’s Pride Corporation (PPC) holds in the production, processing, marketing, and distribution of fresh, frozen, and value-added chicken products to retailers, distributors, and foodservice operators in the United States, Mexico, and Puerto Rico.
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) fell -2.55%, and closed at $11.46. Its volatility for the week is 4.24%, while for the month it is 4.63%. The company has the market capitalization of $1.26 billion. The company holds the book value per share of -0.96, whereas cash per share is 1.16. Price to sale ratio is 11.92. Analysts mean recommendation for the stock is said to be 1.60 (where 1=Buy, 5=sale).
Merrimack Pharmaceuticals Inc (MACK) a biopharmaceutical company holds in discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer mostly in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
